Page 21234..1020..»

Athira Pharma Announces Initiation of Patient Dosing for ACT-AD Clinical Trial of ATH-1017, Small Molecule HGF/MET Activator, for Treatment of…

By Dr. Matthew Watson

SEATTLE, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that patient dosing has begun in ACT-AD, a Phase 2 randomized, placebo-controlled study of ATH-1017 in patients with mild-to-moderate Alzheimer's disease. ATH-1017 is a small molecule therapeutic designed to enhance the activity of Hepatocyte Growth Factor (HGF) and its receptor, MET, which are expressed in the central nervous system, in order to promote brain health and function.

See the original post here:
Athira Pharma Announces Initiation of Patient Dosing for ACT-AD Clinical Trial of ATH-1017, Small Molecule HGF/MET Activator, for Treatment of...

To Read More: Athira Pharma Announces Initiation of Patient Dosing for ACT-AD Clinical Trial of ATH-1017, Small Molecule HGF/MET Activator, for Treatment of…
categoriaGlobal News Feed commentoComments Off on Athira Pharma Announces Initiation of Patient Dosing for ACT-AD Clinical Trial of ATH-1017, Small Molecule HGF/MET Activator, for Treatment of… | dataDecember 1st, 2020
Read All

Aptose to Hold Corporate Update Sunday, December 6th

By Dr. Matthew Watson

Corporate event to provide clinical update for CG-806 in AML and B-cell Cancers

See the article here:
Aptose to Hold Corporate Update Sunday, December 6th

To Read More: Aptose to Hold Corporate Update Sunday, December 6th
categoriaGlobal News Feed commentoComments Off on Aptose to Hold Corporate Update Sunday, December 6th | dataDecember 1st, 2020
Read All

Plus Therapeutics Expands ReSPECT™ Clinical Trial to MD Anderson Cancer Center

By Dr. Matthew Watson

AUSTIN, Texas., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, today announced that the University of Texas MD Anderson Cancer Center is now an active clinical trial site in its ongoing ReSPECT™ Phase 1 clinical trial, currently supported by the National Cancer Institute (NCI). ReSPECT is a multi-center, dose-finding study evaluating the Company’s lead investigational asset, Rhenium NanoLiposome (RNL™), in patients with recurrent glioblastoma (GBM).

Excerpt from:
Plus Therapeutics Expands ReSPECT™ Clinical Trial to MD Anderson Cancer Center

To Read More: Plus Therapeutics Expands ReSPECT™ Clinical Trial to MD Anderson Cancer Center
categoriaGlobal News Feed commentoComments Off on Plus Therapeutics Expands ReSPECT™ Clinical Trial to MD Anderson Cancer Center | dataDecember 1st, 2020
Read All

OpGen Group Company Ares Genetics Advances ares-genetics.cloud Platform, Presents Update at Scientific Conferences, Expects Granting of Key Patent

By Dr. Matthew Watson

Extended collaboration with leading global generics company Sandoz for optimal antibiotic drug positioning by predictive antibiotic susceptibility testing

More here:
OpGen Group Company Ares Genetics Advances ares-genetics.cloud Platform, Presents Update at Scientific Conferences, Expects Granting of Key Patent

To Read More: OpGen Group Company Ares Genetics Advances ares-genetics.cloud Platform, Presents Update at Scientific Conferences, Expects Granting of Key Patent
categoriaGlobal News Feed commentoComments Off on OpGen Group Company Ares Genetics Advances ares-genetics.cloud Platform, Presents Update at Scientific Conferences, Expects Granting of Key Patent | dataDecember 1st, 2020
Read All

Mustang Bio to Host Key Opinion Leader Call on MB-106 for the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

By Dr. Matthew Watson

Call to be held Wednesday, December 9, 2020, at 1:00 p.m. EST Call to be held Wednesday, December 9, 2020, at 1:00 p.m. EST

Continued here:
Mustang Bio to Host Key Opinion Leader Call on MB-106 for the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

To Read More: Mustang Bio to Host Key Opinion Leader Call on MB-106 for the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
categoriaGlobal News Feed commentoComments Off on Mustang Bio to Host Key Opinion Leader Call on MB-106 for the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | dataDecember 1st, 2020
Read All

Allena Pharmaceuticals Announces Appointment of David J. Clark, M.D., M.R.C.P. as Chief Medical Officer

By Dr. Matthew Watson

NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the appointment of David J. Clark, M.D., M.R.C.P, as Chief Medical Officer, effective immediately. Dr. Clark succeeds Annamaria Kausz, M.D., who will transition to supporting the company in an advisory capacity.

See the article here:
Allena Pharmaceuticals Announces Appointment of David J. Clark, M.D., M.R.C.P. as Chief Medical Officer

To Read More: Allena Pharmaceuticals Announces Appointment of David J. Clark, M.D., M.R.C.P. as Chief Medical Officer
categoriaGlobal News Feed commentoComments Off on Allena Pharmaceuticals Announces Appointment of David J. Clark, M.D., M.R.C.P. as Chief Medical Officer | dataDecember 1st, 2020
Read All

FibroGen Announces Retirement of K. Peony Yu, M.D., and Appointment of Mark Eisner, M.D., M.P.H. as Chief Medical Officer

By Dr. Matthew Watson

SAN FRANCISCO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the retirement of K. Peony Yu, M.D., Chief Medical Officer, and appointment of Mark Eisner, M.D., M.P.H. in that role. Dr. Yu will continue as Chief Medical Officer through December 20, 2020, the roxadustat PDUFA date, and will remain with FibroGen through March 15, 2021 serving as Executive Advisor to the CEO to support the transition.

Link:
FibroGen Announces Retirement of K. Peony Yu, M.D., and Appointment of Mark Eisner, M.D., M.P.H. as Chief Medical Officer

To Read More: FibroGen Announces Retirement of K. Peony Yu, M.D., and Appointment of Mark Eisner, M.D., M.P.H. as Chief Medical Officer
categoriaGlobal News Feed commentoComments Off on FibroGen Announces Retirement of K. Peony Yu, M.D., and Appointment of Mark Eisner, M.D., M.P.H. as Chief Medical Officer | dataDecember 1st, 2020
Read All

Agenus Launches Phase 2 Trial Expansion in Colon Cancer for AGEN1181 in Combination with Balstilimab

By Dr. Matthew Watson

New objective response in colon cancer triggers trial expansion New objective response in colon cancer triggers trial expansion

See the original post here:
Agenus Launches Phase 2 Trial Expansion in Colon Cancer for AGEN1181 in Combination with Balstilimab

To Read More: Agenus Launches Phase 2 Trial Expansion in Colon Cancer for AGEN1181 in Combination with Balstilimab
categoriaGlobal News Feed commentoComments Off on Agenus Launches Phase 2 Trial Expansion in Colon Cancer for AGEN1181 in Combination with Balstilimab | dataDecember 1st, 2020
Read All

Zogenix and Leading Experts to Present New Rare Epilepsy Data at AES 2020

By Dr. Matthew Watson

EMERYVILLE, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, announced that data from eleven poster presentations related to FINTEPLA® (fenfluramine) oral solution in Dravet syndrome, Lennox-Gastaut syndrome, and other rare epilepsies will be presented at the American Epilepsy Society (AES) Annual Meeting, being held virtually from December 4-8, 2020. Zogenix will also host a virtual scientific exhibition room and sponsor a continuing medical education (CME) symposium during AES 2020.

View post:
Zogenix and Leading Experts to Present New Rare Epilepsy Data at AES 2020

To Read More: Zogenix and Leading Experts to Present New Rare Epilepsy Data at AES 2020
categoriaGlobal News Feed commentoComments Off on Zogenix and Leading Experts to Present New Rare Epilepsy Data at AES 2020 | dataDecember 1st, 2020
Read All

Histogen Announces Preliminary Week 18 HST-001 Study Results for the Treatment of Androgenic Alopecia in Men

By Dr. Matthew Watson

HST-001 Demonstrated Separation from Placebo at Week 18 Primary Efficacy Endpoint Assessment

Go here to read the rest:
Histogen Announces Preliminary Week 18 HST-001 Study Results for the Treatment of Androgenic Alopecia in Men

To Read More: Histogen Announces Preliminary Week 18 HST-001 Study Results for the Treatment of Androgenic Alopecia in Men
categoriaGlobal News Feed commentoComments Off on Histogen Announces Preliminary Week 18 HST-001 Study Results for the Treatment of Androgenic Alopecia in Men | dataDecember 1st, 2020
Read All

electroCore Announces Selection of gammaCore for National Institute on Drug Abuse (NIDA)-Sponsored Study in Opioid Use Disorders

By Dr. Matthew Watson

BASKING RIDGE, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that its gammaCore non-invasive vagus nerve stimulator (nVNS) has been selected for evaluation in a randomized controlled study for the treatment of opioid use disorders. The study is being run by Dr. Douglas Bremner at Emory University in collaboration with the Georgia Institute of Technology and the City University of New York and is supported by the National Institute on Drug Abuse (NCT04556552).

Excerpt from:
electroCore Announces Selection of gammaCore for National Institute on Drug Abuse (NIDA)-Sponsored Study in Opioid Use Disorders

To Read More: electroCore Announces Selection of gammaCore for National Institute on Drug Abuse (NIDA)-Sponsored Study in Opioid Use Disorders
categoriaGlobal News Feed commentoComments Off on electroCore Announces Selection of gammaCore for National Institute on Drug Abuse (NIDA)-Sponsored Study in Opioid Use Disorders | dataDecember 1st, 2020
Read All

Safe and Efficacious Treatment of Spondylolisthesis via MIS TLIF Approach with the FlareHawk® Expandable Cage

By Dr. Matthew Watson

IJSS-published review finds that the novel biplanar expandable cage provides effective vertebral body slip or spondylolisthesis reduction and improvement in radiographic and clinical parameters with no reported subsidence, migration, or endplate violation IJSS-published review finds that the novel biplanar expandable cage provides effective vertebral body slip or spondylolisthesis reduction and improvement in radiographic and clinical parameters with no reported subsidence, migration, or endplate violation

Link:
Safe and Efficacious Treatment of Spondylolisthesis via MIS TLIF Approach with the FlareHawk® Expandable Cage

To Read More: Safe and Efficacious Treatment of Spondylolisthesis via MIS TLIF Approach with the FlareHawk® Expandable Cage
categoriaGlobal News Feed commentoComments Off on Safe and Efficacious Treatment of Spondylolisthesis via MIS TLIF Approach with the FlareHawk® Expandable Cage | dataDecember 1st, 2020
Read All

VYNE Therapeutics Announces Publication of Long-term Safety & Efficacy Data for ZILXI™ (minocycline) topical foam, 1.5% in the Journal of…

By Dr. Matthew Watson

ZILXI is the First FDA Approved Minocycline Product for the Treatment of Inflammatory Lesions of Rosacea in AdultsZILXI demonstrated a favorable safety and tolerability profile for up to 52 weeks of treatmentEfficacy of ZILXI continued to develop for an additional 40 weeks of treatment after an initial treatment period of 12 weeks

See the original post:
VYNE Therapeutics Announces Publication of Long-term Safety & Efficacy Data for ZILXI™ (minocycline) topical foam, 1.5% in the Journal of...

To Read More: VYNE Therapeutics Announces Publication of Long-term Safety & Efficacy Data for ZILXI™ (minocycline) topical foam, 1.5% in the Journal of…
categoriaGlobal News Feed commentoComments Off on VYNE Therapeutics Announces Publication of Long-term Safety & Efficacy Data for ZILXI™ (minocycline) topical foam, 1.5% in the Journal of… | dataDecember 1st, 2020
Read All

Antios Therapeutics Appoints Gregory T. Mayes Chief Executive Officer

By Dr. Matthew Watson

Former CEO and Antios co-founder, Abel De La Rosa, Ph.D., appointed Chairman of the Board of Directors

Go here to read the rest:
Antios Therapeutics Appoints Gregory T. Mayes Chief Executive Officer

To Read More: Antios Therapeutics Appoints Gregory T. Mayes Chief Executive Officer
categoriaGlobal News Feed commentoComments Off on Antios Therapeutics Appoints Gregory T. Mayes Chief Executive Officer | dataDecember 1st, 2020
Read All

Cidara Therapeutics to Present Preclinical Data for Influenza AVCs at the 7th ESWI Influenza Conference

By Dr. Matthew Watson

SAN DIEGO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced a keynote lecture, an oral presentation and two posters at the 7th European Scientific Working Group on Influenza (ESWI) Influenza Conference, which takes place virtually Dec. 6-9, 2020.

See the original post:
Cidara Therapeutics to Present Preclinical Data for Influenza AVCs at the 7th ESWI Influenza Conference

To Read More: Cidara Therapeutics to Present Preclinical Data for Influenza AVCs at the 7th ESWI Influenza Conference
categoriaGlobal News Feed commentoComments Off on Cidara Therapeutics to Present Preclinical Data for Influenza AVCs at the 7th ESWI Influenza Conference | dataDecember 1st, 2020
Read All

Bellerophon Therapeutics Announces First Patient Enrolled in Phase 3 REBUILD Study Evaluating INOpulse® for the Treatment of Fibrotic Interstitial…

By Dr. Matthew Watson

WARREN, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that the first patient has been enrolled in its REBUILD Phase 3 registrational clinical study evaluating INOpulse®, a pulsed inhaled nitric oxide therapy, as a potential treatment for fibrotic interstitial lung disease (fILD).

See the rest here:
Bellerophon Therapeutics Announces First Patient Enrolled in Phase 3 REBUILD Study Evaluating INOpulse® for the Treatment of Fibrotic Interstitial...

To Read More: Bellerophon Therapeutics Announces First Patient Enrolled in Phase 3 REBUILD Study Evaluating INOpulse® for the Treatment of Fibrotic Interstitial…
categoriaGlobal News Feed commentoComments Off on Bellerophon Therapeutics Announces First Patient Enrolled in Phase 3 REBUILD Study Evaluating INOpulse® for the Treatment of Fibrotic Interstitial… | dataDecember 1st, 2020
Read All

Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

By Dr. Matthew Watson

MONMOUTH JUNCTION, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a?late clinical-stage?biopharmaceutical company?working to develop the first FDA-approved ophthalmic formulation of bevacizumab?for use in retinal?indications, announced today that it has received notification from Nasdaq that it has regained compliance with the minimum bid price for continued listing on the Nasdaq Capital Market, as the closing bid price of Outlook Therapeutics’ common stock has been at $1.00 or greater for 10 consecutive trading days. Accordingly, this matter is now closed.

View original post here:
Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

To Read More: Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
categoriaGlobal News Feed commentoComments Off on Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement | dataDecember 1st, 2020
Read All

Greenwich Biosciences to Present Data on EPIDIOLEX® (cannabidiol) Oral Solution at the American Epilepsy Society Annual Meeting

By Dr. Matthew Watson

- Meeting Highlights Include New Long-Term Data in Tuberous Sclerosis Complex -

See more here:
Greenwich Biosciences to Present Data on EPIDIOLEX® (cannabidiol) Oral Solution at the American Epilepsy Society Annual Meeting

To Read More: Greenwich Biosciences to Present Data on EPIDIOLEX® (cannabidiol) Oral Solution at the American Epilepsy Society Annual Meeting
categoriaGlobal News Feed commentoComments Off on Greenwich Biosciences to Present Data on EPIDIOLEX® (cannabidiol) Oral Solution at the American Epilepsy Society Annual Meeting | dataDecember 1st, 2020
Read All

Better Choice Showing Opportunity for Substantial Monetary Savings from Consolidation of Fulfillment Operations

By Dr. Matthew Watson

Achieving lower costs, while increasing capacity Achieving lower costs, while increasing capacity

Read more:
Better Choice Showing Opportunity for Substantial Monetary Savings from Consolidation of Fulfillment Operations

To Read More: Better Choice Showing Opportunity for Substantial Monetary Savings from Consolidation of Fulfillment Operations
categoriaGlobal News Feed commentoComments Off on Better Choice Showing Opportunity for Substantial Monetary Savings from Consolidation of Fulfillment Operations | dataDecember 1st, 2020
Read All

Auris Medical Reports Positive In vitro Efficacy Data for AM-301 in Protecting Against Sars-CoV-2 Infection

By Dr. Matthew Watson

Hamilton, Bermuda, December 1, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced positive efficacy data from testing AM-301 in vitro. AM-301 is a drug-free nasal spray being developed by the Company’s affiliate Altamira Medica for protection against airborne pathogens and allergens.

Read the original here:
Auris Medical Reports Positive In vitro Efficacy Data for AM-301 in Protecting Against Sars-CoV-2 Infection

To Read More: Auris Medical Reports Positive In vitro Efficacy Data for AM-301 in Protecting Against Sars-CoV-2 Infection
categoriaGlobal News Feed commentoComments Off on Auris Medical Reports Positive In vitro Efficacy Data for AM-301 in Protecting Against Sars-CoV-2 Infection | dataDecember 1st, 2020
Read All

Page 21234..1020..»